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Preventing disease and premature death from chronic diseases requires 
understanding of risk factors and their underlying mechanisms. This 
process is possible with appropriate analyses of individual level data. 
However, to be efficient, data from a large number of individuals are 
usually necessary. Adequate sample sizes can only be reached when 
researchers share individual level data with each other in large 
collaborative efforts. Within Europe, the General Data Protection 
Regulation (GDPR) opens up new possibilities to achieve this goal because 
legislation across the European Economic Area (EEA) has been 
harmonised. 
 
Unfortunately, data sharing outside of the EEA remains difficult. Articles 
45–49 in GDPR provide no straightforward solutions for sharing de-
identified or pseudonymised data outside of the EEA. GDPR combined with 
non-compliant regulations in many countries create serious obstacles to 
wider sharing of data. 
Future European studies can include informed consent with appropriate 
language that will make data sharing easier. However, for studies currently 
being analysed, data were often collected decades ago, without the required 
language in the consents on data sharing outside of the EEA. For older 
European studies with a large number of participants, reconsenting all 
living participants is not practical because of the costs and because one 
cannot find every cohort member decades later. 
Anonymous data fall outside of GDPR, so why not simply anonymise? The 
reason is that the definition of anonymisation according to GDPR is very 
stringent. Thus, for epidemiological and so called big registry data linked to 
detailed cohort data, anonymisation is essentially impossible. 
What do we need to solve this issue? We need the EU Commission and the 
governmental institutions in other countries, such as the USA, to put 
general agreements in place. They must agree on conditions that will 
protect the privacy of the individuals who participated, while 
acknowledging that some parties are not subject to European law. 
What are the consequences of not solving this problem? Diseases such as 
cancer require global efforts. Less data sharing and less research will hurt 
everyone—Europeans, more than anyone. If data and samples from 
Europeans are no longer part of the large international efforts, we will not 
learn whether what holds true in non-EEA collaborations also applies to 
European populations. 
We therefore ask the European Commission to find solutions, in 
collaboration with non-European entities, such that all parties can accept to 
facilitate important research. GDPR should enable and safeguard 
collaborative science, not prevent it. 
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